|
Patrick Celis
Lead Scientific Officer
European Medicines Agency
Amsterdam
Netherlands
|
Patrick Celis joined the European Medicines Agency (EMA) in 1997. He holds a degree in Pharmacy and a PhD in Pharmaceutical Sciences from the University of Leuven, Belgium.
P Celis is Lead Scientific officer in EMA’s Advanced Therapies and Haematological Diseases Office and the Scientific Lead to the Committee for Advanced Therapies (CAT).
P Celis held previous positions in EMA, including the coordination of EU authorisation procedures for biological/biotech products. He was responsible for the following scientific projects: Pandemic influenza vaccines, TSE, viral safety of recombinant products and cell-based medicinal products. He held the positions of Scientific Secretary of the Vaccine Working Party and the Cell-based Products Working Party. Since 2006, he was involved in the implementation of the Regulation on Advanced Therapy Medicinal Products at the EMA.
Prior to joining the EMA, P. Celis worked as Pharmaceutical Assessor at the Belgian Ministry of Health.
P Celis is Lead Scientific officer in EMA’s Advanced Therapies and Haematological Diseases Office and the Scientific Lead to the Committee for Advanced Therapies (CAT).
P Celis held previous positions in EMA, including the coordination of EU authorisation procedures for biological/biotech products. He was responsible for the following scientific projects: Pandemic influenza vaccines, TSE, viral safety of recombinant products and cell-based medicinal products. He held the positions of Scientific Secretary of the Vaccine Working Party and the Cell-based Products Working Party. Since 2006, he was involved in the implementation of the Regulation on Advanced Therapy Medicinal Products at the EMA.
Prior to joining the EMA, P. Celis worked as Pharmaceutical Assessor at the Belgian Ministry of Health.